B
Byoung Chul Cho
Researcher at Yonsei University
Publications - 570
Citations - 23868
Byoung Chul Cho is an academic researcher from Yonsei University. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 57, co-authored 429 publications receiving 15603 citations. Previous affiliations of Byoung Chul Cho include University Health System & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial
Duidui Hong,Amrita Shergill,Lyudmila Bazhenova,Byoung Chul Cho,Rebecca S. Heist,Victor Moreno,Gs. Falchook,Misako Nagasaka,Philippe A. Cassier,Benjamin Besse,D. Kim,S. G. Yoon,Xuan Le,T. Zhao,Siminder K. Atwal,Eric Kristopher Park,J Lee +16 more
TL;DR: Elzovantinib as discussed by the authors is a type I tyrosine kinase inhibitor (TKI) that targets MET, SRC, and CSF1R, including exon 14 skipping (Δex14) mutations.
Journal ArticleDOI
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).
Ji-Youn Han,Myung-Ju Ahn,Sang-We Kim,Ki Hyeong Lee,Eun Kyung Cho,Yun-Gyoo Lee,Dong Wan Kim,Joo Hang Kim,Jong Seok Lee,Gyeong-Won Lee,Byoung Yong Shim,Jin Soo Kim,Sang Hoon Chun,Sung Sook Lee,Young Joo Min,Sang Won Shin,Arielle Yablonovitch,Carin R. Espenschied,Hyunwoo Jang,Byoung Chul Cho +19 more
TL;DR: The EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) patients usually experience improved clinical benefit with EGFR TKIs, but most eventually progress.
Journal ArticleDOI
413OOsimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA
Yuichiro Ohe,S.S. Ramalingam,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Arunee Dechaphunkul,K.H. Lee,Fumio Imamura,Naoyuki Nogami,Ying Cheng,Byoung Chul Cho,E.K. Cho,Johan Vansteenkiste,P.J. Voon,C. Zhou,Jhanelle E. Gray,Rachel Hodge,Yuri Rukazenkov,J-C. Soria +17 more
Journal ArticleDOI
Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))
Stephen V. Liu,F. de Braud,A. Drilon,Robert C. Doebele,Manish R. Patel,Byoung Chul Cho,Myung-Ju Ahn,C.-H. Chiu,Anna F. Farago,Koichi Goto,J.W. Lee,Yuichiro Ohe,S-H.I. Ou,P. A. Cassier,D.S.W. Tan,Gregory A. Otterson,L. Veronese,S. Osborne,B. Simmons,Salvatore Siena +19 more
Journal ArticleDOI
A case of lactic acidosis caused by stavudine in an AIDS patient
Byoung Chul Cho,Sang Hoon Han,Suk Hoon Choi,Jun Yong Choi,Kyung Hee Chang,Young Goo Song,June Myung Kim +6 more
TL;DR: The first Korean case, of severe lactic acidosis in an acquired immunodeficiency syndrome (AIDS) patient receiving stavudine, an anti-HIV drug is reported upon.